What were the considerations made by the committee regarding the cost-effectiveness of NP monitoring?
The committee considered that a 3 month monitoring period every 18 months was a reasonable average, but also recognised that due to the low ICERs that even if the average frequency of monitoring were to be slightly higher that it would still be cost effective. The committee also discussed current practice regarding NP measurement, agreeing that it is usually done at the point of diagnosis. Due to the uncertainty of the cost effectiveness of NP monitoring when the IPD data is used and the potential variation in cost of NP monitoring the committee decided to make a consider recommendation for people under the age of 75 with HF-REF. No economic evaluations were identified for those with heart failure and CKD or AF, and no recommendation was made for this group. Lastly, the committee agreed to exclude a single study from the 2010 update of this question due to it not meeting the review protocol of a minimum of 6 months' follow-up.